SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-19-030768
Filing Date
2019-08-08
Accepted
2019-08-08 16:08:32
Documents
14
Period of Report
2019-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aimt-8k_20190808.htm   iXBRL 8-K 36689
2 EX-99.1 aimt-ex991_6.htm EX-99.1 291442
3 GRAPHIC gfd5mia0jhi3000001.jpg GRAPHIC 8124
  Complete submission text file 0001564590-19-030768.txt   488431

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA aimt-20190808.xsd EX-101.SCH 6197
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aimt-20190808_lab.xml EX-101.LAB 20009
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aimt-20190808_pre.xml EX-101.PRE 12203
7 EXTRACTED XBRL INSTANCE DOCUMENT aimt-8k_20190808_htm.xml XML 3557
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37519 | Film No.: 191009549
SIC: 2834 Pharmaceutical Preparations